Aminosalicylic acid
As of the edition of 20 October 2026, Aminosalicylic acid is a small molecule: marketed, first approved in 1982 (US); acts on PTGS1 and PTGS2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Parasal
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 1 region
- Holder of the most recent approval
- Consolidated Midland; 4 holders in all
- Withdrawn from market
- 4 December 2025 (in some regions)
- Registered trials
- 7, 2 stopped early
- Disease areas
- Digestive system; Immune system; Infections; Urinary and reproductive; Heart and blood vessels; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 4 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 2 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Panray Corp Sub Ormont Drug And Chemical | Acquired holder | 2003 to now |
| Bristol Myers Squibb | Later holder | |
| Concentra Biosciences | Earlier holder | |
| Consolidated Midland | Later holder | |
| Glenwood | Later holder |